Currently, TP53 alteration in CLL is an essential marker for the initiation of novel therapeutic options, such as ibrutinib/idelalisib/acalabrutinib or venetoclax, targeting B-cell receptor signaling or BCL-2, respectively. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.